Using a protein to improve lung transplant outcomes
Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction
This study is looking at how a special protein can help lung transplant patients by reducing inflammation and improving lung function, which may lead to better health and longer survival after their transplant.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Apcbio Innovations, INC. NIH-funded |
| Lab location | 1 site (Frederick, UNITED STATES) |
| Project ID | NIH-10602077 on NIH RePORTER |
What this research studies
This research investigates the use of recombinant human CC10 protein to treat and prevent chronic lung allograft dysfunction (CLAD) in patients who have undergone lung transplants. The approach focuses on enhancing the body's natural defense mechanisms in the lungs, which are often compromised after transplantation. By administering this protein, the study aims to reduce inflammation and improve lung function, potentially leading to better long-term survival rates for transplant recipients. The research builds on previous findings that demonstrated the protein's safety and efficacy in animal models and premature infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received a lung transplant and are at risk for chronic lung allograft dysfunction.
Not a fit: Patients who have not undergone lung transplantation or those with other unrelated respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the survival and quality of life for lung transplant patients by reducing the incidence of chronic lung allograft dysfunction.
How similar studies have performed: Previous studies have shown promising results with similar biologic therapies, indicating potential for success in this novel application.
Where this research is happening
Frederick, UNITED STATES
- Apcbio Innovations, INC. — Frederick, United States (Active)
Researchers
- Principal investigator: Pilon, Aprile L — Apcbio Innovations, INC.
- Study coordinator: Pilon, Aprile L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.